• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4601862)   Today's Articles (3886)   Subscriber (49365)
For: Hank JA, Weil-Hillman G, Surfus JE, Sosman JA, Sondel PM. Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. Cancer Immunol Immunother 1990;31:53-9. [PMID: 2306756 PMCID: PMC11038065 DOI: 10.1007/bf01742496] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/1989] [Accepted: 08/30/1989] [Indexed: 12/31/2022]
Number Cited by Other Article(s)
1
Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. ANNALS OF TRANSLATIONAL MEDICINE 2019;7:105. [PMID: 31019955 DOI: 10.21037/atm.2019.01.42] [Citation(s) in RCA: 112] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
2
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol 2011;2011:379123. [PMID: 21660134 PMCID: PMC3110303 DOI: 10.1155/2011/379123] [Citation(s) in RCA: 113] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2011] [Accepted: 03/16/2011] [Indexed: 01/08/2023]  Open
3
Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim KM, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KD, London WB, Seeger RC, Maris JM, Sondel PM. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 2010;70:9554-61. [PMID: 20935224 PMCID: PMC2999644 DOI: 10.1158/0008-5472.can-10-2211] [Citation(s) in RCA: 143] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
4
Quan, Jr. WD, Quan FM. Activity of Continuous Infusion + Pulse Interleukin-2 with Famotidine in Metastatic Melanoma. Cancer Biother Radiopharm 2009;24:1-6. [DOI: 10.1089/cbr.2008.0540] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
5
Tyre CC, Quan W. Nursing Care of Patients Receiving High-Dose, Continuous-Infusion Interleukin-2 With Pulse Dose and Famotidine. Clin J Oncol Nurs 2007;11:513-9. [PMID: 17723964 DOI: 10.1188/07.cjon.513-519] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
6
Quan WDY, Milligan KS, Quan FM, Cuenca RE, Khan N, Liles DK, Walker PR. Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma. Cancer Biother Radiopharm 2007;21:607-12. [PMID: 17257076 DOI: 10.1089/cbr.2006.21.607] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
7
Quan WDY, Walker PR, Quan FM, Ramirez M, Elsamaloty HM, Ghai V, Vinogradov M, Liles DK. Activity of Continuous Infusion Plus Pulse Interleukin-2 with Famotidine in Patients with Metastatic Kidney Cancer or Melanoma Previously Treated with Interleukin-2. Cancer Biother Radiopharm 2006;21:437-42. [PMID: 17105418 DOI: 10.1089/cbr.2006.21.437] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
8
Walker PR, Khuder SA, Quan WDY. Continuous Infusion Interleukin-2 and Antihistamines in Metastatic Kidney Cancer. Cancer Biother Radiopharm 2005;20:487-90. [PMID: 16248764 DOI: 10.1089/cbr.2005.20.487] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
9
Quan W, Ramirez M, Taylor C, Vinogradov M, Quan F, Khan N. High-Dose Continuous Infusion Plus Pulse Interleukin-2 and Famotidine in Metastatic Kidney Cancer. Cancer Biother Radiopharm 2005;20:36-40. [PMID: 15778577 DOI: 10.1089/cbr.2005.20.36] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
10
Quan W, Ramirez M, Taylor WC, Vinogradov M, Khan N, Jackson S. High-Dose Continuous Infusion Plus Pulse Interleukin-2 and Famotidine in Melanoma. Cancer Biother Radiopharm 2004;19:770-5. [PMID: 15665626 DOI: 10.1089/cbr.2004.19.770] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
11
King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 2004;22:4463-73. [PMID: 15483010 PMCID: PMC2367368 DOI: 10.1200/jco.2004.11.035] [Citation(s) in RCA: 103] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
12
Shu L, Qi CF, Hand PH, Schlom J, Kashmiri SV. Generation and characterization of a single-gene encoded single-chain immunoglobulin-interleukin-2 fusion protein. IMMUNOTECHNOLOGY : AN INTERNATIONAL JOURNAL OF IMMUNOLOGICAL ENGINEERING 1995;1:231-41. [PMID: 9373351 DOI: 10.1016/1380-2933(95)00025-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
13
Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci U S A 1994;91:9626-30. [PMID: 7937818 PMCID: PMC44866 DOI: 10.1073/pnas.91.20.9626] [Citation(s) in RCA: 71] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]  Open
14
Helfand SC, Soergel SA, MacWilliams PS, Hank JA, Sondel PM. Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs. Cancer Immunol Immunother 1994;39:84-92. [PMID: 8044833 PMCID: PMC11038981 DOI: 10.1007/bf01525313] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/1993] [Accepted: 03/29/1994] [Indexed: 01/28/2023]
15
Helfand SC, Soergel SA, Modiano JF, Hank JA, Sondel PM. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro. CANCER BIOTHERAPY 1994;9:237-44. [PMID: 7820185 DOI: 10.1089/cbr.1994.9.237] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
16
Yeung AW, Pang YK, Tsang YC, Wong SW, Leung JS. Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study trial. Cancer 1993;71:3633-9. [PMID: 8387882 DOI: 10.1002/1097-0142(19930601)71:11<3633::aid-cncr2820711127>3.0.co;2-c] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
17
Albertini MR, Hank JA, Sondel PM. Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2. BIOTHERAPY (DORDRECHT, NETHERLANDS) 1992;4:189-98. [PMID: 1599802 DOI: 10.1007/bf02174205] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
18
Hayat K, Rodgers S, Bruce L, Rees RC, Chapman K, Reeder S, Dorreen MS, Sheridan E, Sreenivasan T, Hancock BW. Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2. Eur J Cancer 1991;27:1009-14. [PMID: 1832884 DOI: 10.1016/0277-5379(91)90270-n] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
19
Hermann GG, Geertsen PF, von der Maase H, Zeuthen J. Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma. Cancer Immunol Immunother 1991;34:111-4. [PMID: 1760814 PMCID: PMC11038133 DOI: 10.1007/bf01741344] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/1991] [Accepted: 07/10/1991] [Indexed: 12/28/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA